Compare VENUS REMEDIES with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs WOCKHARDT - Comparison Results

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES WOCKHARDT VENUS REMEDIES/
WOCKHARDT
 
P/E (TTM) x -1.1 -21.0 - View Chart
P/BV x 0.1 1.1 7.0% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VENUS REMEDIES   WOCKHARDT
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
WOCKHARDT
Mar-18
VENUS REMEDIES/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs1261,012 12.4%   
Low Rs61532 11.5%   
Sales per share (Unadj.) Rs301.8355.9 84.8%  
Earnings per share (Unadj.) Rs-24.9-60.3 41.3%  
Cash flow per share (Unadj.) Rs2.5-46.8 -5.4%  
Dividends per share (Unadj.) Rs00.01 0.0%  
Dividend yield (eoy) %00 0.0%  
Book value per share (Unadj.) Rs293.3257.8 113.8%  
Shares outstanding (eoy) m12.34110.63 11.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.2 14.3%   
Avg P/E ratio x-3.8-12.8 29.4%  
P/CF ratio (eoy) x36.7-16.5 -222.6%  
Price / Book Value ratio x0.33.0 10.6%  
Dividend payout %00 0.0%   
Avg Mkt Cap Rs m1,15485,379 1.4%   
No. of employees `0000.96.3 14.8%   
Total wages/salary Rs m3939,371 4.2%   
Avg. sales/employee Rs Th4,026.16,295.0 64.0%   
Avg. wages/employee Rs Th425.01,498.3 28.4%   
Avg. net profit/employee Rs Th-331.8-1,066.3 31.1%   
INCOME DATA
Net Sales Rs m3,72439,369 9.5%  
Other income Rs m231,202 1.9%   
Total revenues Rs m3,74740,571 9.2%   
Gross profit Rs m39518 2,157.4%  
Depreciation Rs m3381,495 22.6%   
Interest Rs m3542,555 13.9%   
Profit before tax Rs m-275-2,830 9.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m32257 12.3%   
Profit after tax Rs m-307-6,669 4.6%  
Gross profit margin %10.60 22,806.5%  
Effective tax rate %-11.5-9.1 126.4%   
Net profit margin %-8.2-16.9 48.7%  
BALANCE SHEET DATA
Current assets Rs m2,63833,796 7.8%   
Current liabilities Rs m2,30526,917 8.6%   
Net working cap to sales %8.917.5 51.2%  
Current ratio x1.11.3 91.2%  
Inventory Days Days13579 170.7%  
Debtors Days Days4689 51.9%  
Net fixed assets Rs m4,87139,664 12.3%   
Share capital Rs m123553 22.3%   
"Free" reserves Rs m3,49627,968 12.5%   
Net worth Rs m3,61928,522 12.7%   
Long term debt Rs m1,37421,731 6.3%   
Total assets Rs m7,50981,620 9.2%  
Interest coverage x0.2-0.1 -207.4%   
Debt to equity ratio x0.40.8 49.8%  
Sales to assets ratio x0.50.5 102.8%   
Return on assets %0.6-5.0 -12.5%  
Return on equity %-8.5-23.4 36.3%  
Return on capital %1.6-7.7 -20.6%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m09,807 0.0%   
Fx outflow Rs m5171,789 28.9%   
Net fx Rs m-5178,019 -6.4%   
CASH FLOW
From Operations Rs m514684 75.2%  
From Investments Rs m-1236,302 -2.0%  
From Financial Activity Rs m-387-7,695 5.0%  
Net Cashflow Rs m4-664 -0.6%  

Share Holding

Indian Promoters % 32.9 74.5 44.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 2.3 7.8%  
FIIs % 0.6 7.7 7.5%  
ADR/GDR % 0.0 0.1 -  
Free float % 66.4 15.4 431.2%  
Shareholders   20,121 67,757 29.7%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   PFIZER  GSK PHARMA  PANACEA BIOTECH  DR. REDDYS LAB  ABBOTT INDIA  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 21 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day marginally higher.

Related Views on News

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (3QFY19); Net Profit Down 80.6% (Quarterly Result Update)

Jan 29, 2019 | Updated on Jan 29, 2019

For the quarter ended December 2018, WOCKHARDT LTD. has posted a net profit of Rs 769 m (down 80.6% YoY). Sales on the other hand came in at Rs 10 bn (up 4.0% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)

Oct 30, 2019

Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Nov 11, 2019 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS